Moore K., Colombo N., Scambia G., Kim B.G., Oaknin A., Friedlander M. et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495–2505. https://doi.org/10.1056/nejmoa1810858..
DOI: 10.1056/nejmoa1810858
DiSilvestro P., Banerjee S., Colombo N., Scambia G., Kim B.G., Oaknin A. et al. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. J Clin Oncol. 2023;41(3):609–617. https://doi.org/10.1200/JCO.22.01549..
DOI: 10.1200/JCO.22.01549
Harter P., Mouret-Reynier M.A., Pignata S., Cropet C., González-Martín A., Bogner G. et al. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Gynecol Oncol. 2022;164(2):254–264. https://doi.org/10.1016/j.ygyno.2021.12.016..
DOI: 10.1016/j.ygyno.2021.12.016
Ray-Coquard I., Pautier P., Pignata S., Pérol D., González-Martín A., Berger R. et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381(25):2416–2428. https://doi.org/10.1056/NEJMoa1911361..
DOI: 10.1056/NEJMoa1911361
Monk B.J., Parkinson C., Lim M.C., O’Malley D.M., Oaknin A., Wilson M.K. et al. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022;40(34):3952–3964. https://doi.org/10.1200/JCO.22.01003..
DOI: 10.1200/JCO.22.01003
González-Martín A., Pothuri B., Vergote I., DePont Christensen R., Graybill W., Mirza M.R. et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381(25):2391–2402. https://doi.org/10.1056/NEJMoa1910962..
DOI: 10.1056/NEJMoa1910962
Coleman R.L., Fleming G.F., Brady M.F., Swisher E.M., Steffensen K.D., Friedlander M. et al. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019;381(25):2403–2415. https://doi.org/10.1056/NEJMoa1909707..
DOI: 10.1056/NEJMoa1909707
Ray-Coquard I., Leary A., Pignata S., Cropet C., González-Martín A., Bogner G. et al. Final overall survival results from the Phase III PAOLA-1/ENGOTov25 trial evaluating maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer. Ann Oncol. 2022;33(7 Suppl.):S1396–S1397. https://doi.org/10.1016/j.annonc.2022.08.025..
DOI: 10.1016/j.annonc.2022.08.025
Тюляндина А.С., Коломиец Л.А., Морхов К.Ю., Нечушкина В.М., Покатаев И.А., Румянцев А.А. и др. Практические рекомендации по лекарственному лечению рака яичников, первичного рака брюшины и рака маточных труб. Злокачественные опухоли. 2022;12(3s2):198–211. https://doi.org/10.18027/2224-5057-2022-12-3s2-198-211..
DOI: 10.18027/2224-5057-2022-12-3s2-198-211
Rustin G.J., van der Burg M.E., Griffin C.L., Guthrie D., Lamont A., Jayson G.C. et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155–1163. https://doi.org/10.1016/s0140-6736(10)61268-8..
DOI: 10.1016/s0140-6736(10)61268-8
Vergote I., Gonzalez-Martin A., Lorusso D., Gourley C., Mirza M.R., Kurtz J.E. et al. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. Lancet Oncol. 2022;23(8):e374–e384. https://doi.org/10.1016/S1470-2045(22)00139-5..
DOI: 10.1016/S1470-2045(22)00139-5
Harter P., du Bois A., Hahmann M., Hasenburg A., Burges A., Loibl S. et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702–1710. https://doi.org/10.1245/s10434-006-9058-0..
DOI: 10.1245/s10434-006-9058-0
Harter P., Sehouli J., Reuss A., Hasenburg A., Scambia G., Cibula D. et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21(2):289–295. https://doi.org/10.1097/IGC.0b013e31820aaafd..
DOI: 10.1097/IGC.0b013e31820aaafd
Harter P., Sehouli J., Vergote I., Ferron G., Reuss A., Meier W. et al. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. N Engl J Med. 2021;385(23):2123–2131. https://doi.org/10.1056/NEJMoa2103294..
DOI: 10.1056/NEJMoa2103294
Poveda A., Floquet A., Ledermann J.A., Asher R., Penson R.T., Oza A.M. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):620–631. https://doi.org/10.1016/S1470-2045(21)00073-5..
DOI: 10.1016/S1470-2045(21)00073-5
Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–1392. https://doi.org/10.1056/NEJMoa1105535..
DOI: 10.1056/NEJMoa1105535
Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852–861. https://doi.org/10.1016/S1470-2045(14)70228-1..
DOI: 10.1016/S1470-2045(14)70228-1
Coleman R.L., Brady M.F., Herzog T.J., Sabbatini P., Armstrong D.K., Walker J.L. et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779–791. https://doi.org/10.1016/S1470-2045(17)30279-6..
DOI: 10.1016/S1470-2045(17)30279-6
Coleman R.L., Spirtos N.M., Enserro D., Herzog T.J., Sabbatini P., Armstrong D.K. et al. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019;381(20):1929–1939. https://doi.org/10.1056/NEJMoa1902626..
DOI: 10.1056/NEJMoa1902626
Ehmann S., Zivanovic O., Chi D.S. Why was GOG-0213 a negative trial? J Gynecol Oncol. 2021;32(1):e19. https://doi.org/10.3802/jgo.2021.32.e19..
DOI: 10.3802/jgo.2021.32.e19
Baek M.H., Park E.Y., Ha H.I., Park S.Y., Lim M.C., Fotopoulou C. et al. Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis. J Clin Oncol. 2022;40(15):1659–1670. https://doi.org/10.1200/JCO.21.02085..
DOI: 10.1200/JCO.21.02085
Frenel J.S., Kim J.W., Aryal N., Asher R., Berton D., Vidal L. et al. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. Ann Oncol. 2022;33(10):1021–1028. https://doi.org/10.1016/j.annonc.2022.06.011..
DOI: 10.1016/j.annonc.2022.06.011
Jiang X., Li X., Li W., Bai H., Zhang Z. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. J Cell Mol Med. 2019;23(4):2303–2313. https://doi.org/10.1111/jcmm.14133..
DOI: 10.1111/jcmm.14133
Ray Chaudhuri A., Callen E., Ding X., Gogola E., Duarte A.A., Lee J.E. et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016;535(7612):382–387. https://doi.org/10.1038/nature18325..
DOI: 10.1038/nature18325
Schlacher K. PARPi focus the spotlight on replication fork protection in cancer. Nat Cell Biol. 2017;19(11):1309–1310. https://doi.org/10.1038/ncb3638..
DOI: 10.1038/ncb3638
Färkkilä A., Rodríguez A., Oikkonen J., Gulhan D.C., Nguyen H., Domínguez J. et al. Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells. Cancer Res. 2021;81(10):2774–2787. https://doi.org/10.1158/0008-5472.CAN-20-2912..
DOI: 10.1158/0008-5472.CAN-20-2912
Palluzzi E., Marchetti C., Cappuccio S., Avesani G., Macchia G., Gambacorta M.A. et al. Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance. Int J Gynecol Cancer. 2022;32(9):1164–1170. https://doi.org/10.1136/ijgc-2022-003543..
DOI: 10.1136/ijgc-2022-003543
Gauduchon T., Kfoury M., Lorusso D., Floquet A., Ventriglia J., Salaun H. et al. PARP inhibitors (PARPi) prolongation after local therapy for oligometastatic progression in relapsed ovarian cancer patients. Gynecol Oncol. 2023;173:98–105. https://doi.org/10.1016/j.ygyno.2023.04.002..
DOI: 10.1016/j.ygyno.2023.04.002
Cerda V.R., Lu D., Scott M., Kim K.H., Rimel B.J., Kamrava M. Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: a cross-sectional study. Int J Gynecol Cancer. 2022;32(2):153–158. https://doi.org/10.1136/ijgc-2021-003053..
DOI: 10.1136/ijgc-2021-003053
Perez-Lopez R., Roda D., Jimenez B., Brown J., Mateo J., Carreira S. et al. High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. Oncotarget. 2017;8(61):104430–104443. https://doi.org/10.18632/oncotarget.22303..
DOI: 10.18632/oncotarget.22303